In conclusion, we report on the design and development of a novel MUC16-targeted antibody MRI probe to diagnose MUC16-expressing pancreatic cancer in the early stages with smaller lesions and under aggressive disease burden with sizable tumors. Here, MUC16 is linked to pancreatic neoplasm.